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to provide essential information for busy echo‑
cardiography teams facing epidemic threat.
Etiology, epidemiology, clinical presentation, 
diagnostic workup, and course of coronavi‑
rus disease 2019 Coronavirus disease 2019 
is caused by severe acute respiratory syndrome 
coronavirus 2 (SARS ‑CoV‑2).1 The first cases of 
this disease occurred in the city of Wuhan, Chi‑
na in December 2019, where—as it is suspect‑
ed—zoonotic transmission of the coronavirus 
Introduction In view of the rapidly evolving 
coronavirus disease 2019 (COVID‑19) pandemic, 
there is an urgent need to reorganize the work 
of echocardiography laboratories in order to 
ensure the safety of patients and protection of 
physicians, technicians, and other staff mem‑
bers. We summarize briefly the nature of COV‑
ID‑19 disease, its epidemiology, basic symptoms, 
cardiovascular complications, diagnostic ultra‑
sound procedures (including lung ultrasound) as 


















Transthoracic and transesophageal echocardiography may be required in patients with coronavirus 
disease 2019 (COVID‑19), resulting in direct contact with the patient and risk of transmitting the  infection 
from patients to medical personnel. Therefore, we recommend to perform problem ‑oriented time ‑limited 
transthoracic examinations. Whenever possible, examinations should be analyzed offline, outside 
the isolation zones. Transesophageal echocardiography is considered an aerosol ‑generating procedure 
and should be performed only as a lifesaving procedure. Personnel should use appropriate personal 
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in ‑hospital death on admission are: older age, 
higher SOFA (Sequential Organ Failure Assess‑
ment) score, and D ‑dimer concentration over 
1 μg/ml, indicators which are observed in se‑
vere pneumonia.8 The case fatality rate of CO‑
VID‑19 in the overall population is estimated 
at 2.3%, it is minimal in young healthy individ‑
uals, but it reaches 14.8% or more in patients 
over 80 years of age.7
Coronavirus disease 2019 and cardiovascu‑
lar diseases SARS ‑CoV‑2 is particularly dan‑
gerous to cardiac patients. It invades the lungs 
and causes interstitial pneumonia with the dy‑
namic destruction of the alveoli and develop‑
ment of ARDS. Severely depressed gas exchange, 
accompanied by insufficiently active or hyper‑
‑regulated immune system, add a risk of mortal‑
ity, mostly in patients with coexisting illnesses, 
particularly cardiovascular disease.
There are also reports about direct acute 
and chronic damage caused by SARS ‑CoV‑2 to 
the cardiovascular system.9 The infection has 
been associated with the development of myo‑
carditis, arrhythmias, heart failure, myocardial 
infarction, and thromboembolism.10 In Wuhan, 
it has been observed that patients treated in in‑
tensive care units had significantly higher car‑
diac troponin levels comparing with other pa‑
tients.11 Among those who died from COVID‑19, 
11.8% of patients without a history of previous 
heart disease had elevated troponin concentra‑
tions. It was estimated that 7% of deaths were 
caused by myocarditis with heart failure, and 
overall myocarditis might have been implicated 
in 33% of deaths.12 Fulminant myocarditis has 
also been reported in some patients effectively 
treated with steroids and immunoglobulins.13 As 
a result, Chinese authors recommend transtho‑
racic echocardiography in all patients with com‑
plicated COVID‑19 disease.14 Apart from respi‑
ratory failure, the typical mode of death is dis‑
tributive or cardiogenic shock.15 Neither peri‑
cardial nor pleural effusion is a typical finding 
in COVID‑19.
Patients with cardiovascular disease repre‑
sent a large proportion of deaths from COVID‑19. 
In the  meta ‑analysis of 1527 patients with 
COVID‑19, the prevalence of hypertension was 
17.1%, cardiac and cerebrovascular disease, 16.4%, 
and diabetes, 9.7%.16 In a series of 44 672 pa‑
tients, a subset of patients with cardiovascular 
disease had 10.5% mortality. There is a higher 
probability of heart failure following infection 
which leads to a vicious circle of cardiorespira‑
tory failure and shock.
It is also likely that patients with previ‑
ous cardiovascular disease and early com‑
plaints caused by the  infection may seek 
help in cardiology clinics and departments 
before the infection is confirmed. Thus, due 
to the prevalent coincidence of previous or 
and its mutation, allowing the spread of infec‑
tion between people, took place.2 Due to the rap‑
id increase in the number of cases, first in China 
and then in other parts of the world, the World 
Health Organization announced the COVID‑19 
pandemic on March 11, 2020. Current epidemi‑
ological data are available on the Worldome‑
ter website.3
In Poland, ordinances of the  Minister of 
Health introduced the state of epidemiological 
threat first, and on March 20, 2020, the state of 
the COVID‑19 epidemic.
The transmission of SARS ‑CoV‑2 occurs main‑
ly through the droplet route, but the possibili‑
ty of airborne transmission and transmission 
through the fecal ‑oral route is also postulat‑
ed, though the latter seems less relevant so 
far.4 The estimated median incubation time for 
COVID‑19 is 5.1 days, and only 2.5% of patients 
develop symptoms within 2.2 days after infec‑
tion, whereas 97.5% of patients develop symp‑
toms within 11.5 days after infection.5 The most 
common symptoms are: fever, cough, fatigue, 
and shortness of breath, occurring on average 
in 91%, 67%, 51% and 30% of patients, respec‑
tively. The median time from onset of symptoms 
to dyspnea is 7 days. The most common comor‑
bidities present in patients with SARS ‑CoV‑2 
infection include hypertension and other car‑
diovascular diseases, diabetes, and chronic ob‑
structive pulmonary disease. Their prevalence 
is higher in patients with severe disease.6 More 
male than female patients are affected.
Definitive diagnosis of SARS ‑CoV‑2 infection 
is based primarily on nucleic acid amplification 
tests, such as real ‑time reverse transcriptase–
polymerase chain reaction (rRT ‑PCR).
In about 81% of patients, the disease is mild 
and does not require hospitalization, in 14% 
it is severe, and in 5% it is critical.7 The most 
common complications include sepsis, acute 
respiratory distress syndrome (ARDS), heart 
failure, and septic shock. The risk factors for 
TABLE 1 Key messages for performing echocardiography
Ensure adequate medical personnel protection equipment
Ensure effective laboratory disinfection procedures
Ensure adequate training in personnel protection equipment use and laboratory 
disinfection
If possible, dedicate scanners to isolation areas
Consider using handheld or portable machines when available
Identify, defer, or eliminate previously planned elective echocardiography
Routine echocardiography in unselected patients with COVID‑19 is not recommended
Limit direct interaction with patients by promoting problem ‑oriented examinations in 
medium ‑high‑risk patients in whom the examination may significantly contribute to 
the change in management
Perform transesophageal examinations only if absolutely needed and with full 
personal protection equipment
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of the examination  might significantly affect 
patient management. Elective examinations in 
stable patients and those with good clinical con‑
dition, without new electrocardiographic chang‑
es, dyspnea and / or tachycardia, and normal ox‑
ygen saturation (>93%) should be deferred.
Whenever possible, analyses and measure‑
ments should be performed offline, outside 
the contaminated area. Shortened echocardio‑
graphy reports are recommended, provided they 
are sufficient to cover all clinically important el‑
ements. To avoid nondiagnostic examinations, 
the ultrasonic contrast, if available, may be use‑
ful to improve image quality. Other imaging op‑
tions, such as computed tomography, should be 
considered as complementary or alternative de‑
pending on the clinical question ‑oriented di‑
agnostic plan.
Point ‑of ‑care cardiac / lung ultrasound Point‑
‑of ‑care cardiac ultrasound may play an impor‑
tant role in the care of patients with COVID‑19, 
as it can be performed by properly trained cli‑
nicians directly involved in patient care, ob‑
viating the need to enter and leave the isola‑
tion zones. It may also be an alternative to lung 
auscultation.19
Point ‑of ‑care cardiac ultrasound focuses on 
confirming or excluding a specific diagnosis to 
facilitate therapeutic decisions. It is not equiva‑
lent to standard echocardiography as it has lim‑
ited diagnostic capabilities. Simplified construc‑
tion of handheld echocardiography machines 
(sometimes limited to the transducer connect‑
ed to a tablet or a smartphone), which may be 
used for this purpose, is an advantage, espe‑
cially in isolation units or intensive care units, 
where the movement of large equipment is dif‑
ficult. Importantly, it facilitates rapid and effec‑
tive disinfection of the device, reducing the risk 
of transmission of COVID‑19. As patients are 
not allowed to leave isolation wards, eliminating 
the need to transport them to the echocardio‑
graphy laboratory is crucial.
In the age of SARS ‑CoV‑2 infections, ultra‑
sound evaluation of the lung may be useful. It 
should not be used to confirm or exclude COV‑
ID‑19 and is also currently not recommended as 
a screening tool, though lung abnormalities de‑
tected in COVID‑19 may be present in the early 
stages of the disease, sometimes preceding oth‑
er clinical manifestations.
The most common changes present in point‑
‑of ‑care lung ultrasound in COVID‑19 are: 
pleural line abnormalities, B ‑line artifacts, 
and consolidation. Pleural line is normal‑
ly about 1 mm thick but in COVID‑19 it may 
thicken, appear irregular, and lose its conti‑
nuity. B ‑line artifacts are the earliest signs in 
the disease course. They are a sensitive mar‑
ker of fluid accumulation in the interstitial 
space. It should be remembered that they are 
acute cardiovascular disease, cardiologists 
will frequently be involved in the treatment 
of COVID‑19 patients, also those with no spe‑
cific signs of infectious disease. Reports from 
China and Italy emphasize the importance of 
evaluating cardiac function of hospitalized pa‑
tients with COVID‑19. 17
Echocardiography and ultrasound proto‑
cols in the era of pandemic The key mes‑
sages from our expert opinion are presented 
in TABLE 1. According to the American Society of 
Echocardiography, ultrasound techniques play 
an important role in the management of pa‑
tients with COVID‑19. Due to the high preva‑
lence of myocarditis and heart failure, transtho‑
racic echocardiography is routinely recommend‑
ed in patients with complicated COVID‑19 in or‑
der to differentiate causes of dyspnea and moni‑
tor the sequelae of ARDS. Echocardiography may 
be used to monitor fluid management in shock 
or extracorporeal membrane oxygenation. We 
recommend to perform echocardiography selec‑
tively, only in hospitalized patients with either 
signs of heart failure / hemodynamic compro‑
mise or unexplained deterioration of their clin‑
ical status, if cardiac dysfunction is suspected. 
Routine echocardiography in all patients with 
COVID‑19 is not recommended.
Performing the examinations requires di‑
rect contact with the patient and poses a risk 
of infection transmission both from patient 
to personnel, not only by symptomatic SARS‑
‑CoV‑2‑positive patients but also by undeter‑
mined cases and asymptomatic carriers.18 This 
is particularly important in case of transesoph‑
ageal echocardiography since this is an aerosol 
generating procedure that may cause prolonged 
risk of airborne transmission by direct inhala‑
tion or contamination.
Personal protection is of key importance. It 
is estimated that medical personnel represent 
approximately 10% of Italian patients with CO‑
VID‑19. Depending on local recommendations, 
staff with particular risk factors, such as ad‑
vanced age, chronic conditions, pregnancy, or 
immunosuppression, may be advised not to have 
contact with patients with COVID‑19. The dura‑
tion of the examination should be limited to ob‑
taining all clinically useful and important infor‑
mation as quickly as possible. Problem ‑oriented 
examinations are recommended, focused mainly 
on the identification of the most important ab‑
normalities, such as: global or regional myocar‑
dial dysfunction, severe valvular disease, peri‑
cardial fluid, and vegetations. It is of utmost 
importance to perform echocardiography ap‑
propriately and avoid unnecessary examina‑
tions not affecting treatment decisions. An ex‑
amination should be repeated only in the case 
of clear clinical deterioration, when cardiac in‑
volvement is strongly suspected, and the result 
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recommend at least surgical mask (type IIR), 
plastic apron.
The time of direct contact with the patient 
should be kept to a minimum. With the right‑
‑handed scanning, tests should be carried out 
with the patient positioned on the left side, 
that is, with the back to the examiner. Gloves 
should be discarded after each test (wash and 
disinfect hands thereafter), the mask can be 
used without removing for up to 6 hours when 
caring for a cohort of COVID‑19 patients. Oth‑
er elements of the outfit, depending on their 
availability, should be used for no more than 
6 to 8 hours. No one should leave the exam‑
ination room into the clean area in the con‑
taminated personal protective equipment. Pa‑
tient undergoing the examination must wear 
a surgical mask, protecting against droplet 
transmission. A person not directly partici‑
pating in the examination (eg, a technician) 
should keep a distance of at least 1.5 meters 
from the patient.
Since echocardiography devices are equipped 
with airflow cooling fans, air streams should be 
directed away from the staff. Optimally, there 
should be a continuously operating plasma air 
purifier in the room, preferably situated near 
the echocardiography machine. If not available, 
the laboratory should be cleaned 3 times a day 
with an ultraviolet lamp. The echocardiography 
ultrasound machine and examining beds should 
be fully wiped out after each examination. De‑
tailed guidelines on how to clean ultrasound 
machines should be developed in cooperation 
with the manufacturers.24,25 The American In‑
stitute for Ultrasound in Medicine recommenda‑
tions can help in this regard.26 Dedicated clean‑
ing wipes should be used to clean the probe, ca‑
bles, keyboard, screen, and all other elements. If 
wipes are not available, alcohol may be used on 
most of the elements but it can damage the probe 
lens or the screen and it should not be applied 
directly but by using soaked cloths. The elec‑
tronic probe connector should be kept dry and 
untouched. Rooms should be cleaned at least 3 
times a day and every time after they get con‑
taminated. Cleaning staff should be appropri‑
ately trained and protected. Detailed recommen‑
dations remain the responsibility of individu‑
al centers.
In case of transthoracic echocardiography per‑
formed outside the echocardiography laborato‑
ry, that is, at bedside, the machines should be 
cleaned when leaving the patient rooms, not af‑
ter returning to the echocardiography laborato‑
ry. The use of portable machines that are easy to 
disinfect should be strongly considered. In case 
of transthoracic echocardiography performed in 
the areas at risk of airborne transmission, such 
as operating theaters, intensive care units, pre‑
cautions should be identical as for transesopha‑
geal echocardiography (see below).
nonspecific and present in other diseases, espe‑
cially in heart failure. Their location and densi‑
ty vary significantly, including focal, multifo‑
cal, and confluent patterns. Increased density 
leading to the image of a “white lung” (equiva‑
lent of the ground glass opacities on chest to‑
mography) indicates more advanced disease, 
and its disappearance heralds the healing pro‑
cess. Consolidations are pathological airless 
areas of different shape and size. In patients 
with COVID‑19, subpleural consolidations are 
most frequently seen. The appearance of flu‑
id in the pleural cavity is a rare phenomenon 
in the course of COVID‑19. A ‑lines can be ob‑
served during the recovery phase. However, 
these lesions are not specific for COVID‑19 and 
may be present in other types of pneumonia. 
A clear and simple guide to pulmonary lung 
ultrasound in patients with COVID‑19 can be 
found online both in English and in Polish.20,21
Echocardiography laboratory setup When 
organizing work in the echocardiography labo‑
ratory, the World Health Organization recom‑
mendations on the types of personal protec‑
tive equipment used in the context of COVID‑19 
may be accommodated, taking into account 
the circumstances, staff, and scope of activi‑
ties.22 Two types of transmission routes, drop‑
let and airborne, should be taken into account. 
The first is mainly related to performing exami‑
nations in the presence of SARS ‑CoV‑2‑positive 
patients in rooms when proper distancing is 
not observed (at least about 1.5 to 2 m) from 
the infected, the second is related to aerosol‑
‑generating procedures, such as transesopha‑
geal echocardiography.
Transthoracic echocardiography The use 
of dedicated ultrasound machines (also gel and 
probe covers) that do not leave contaminated 
areas is preferred. This is especially important 
in the isolation zones with the risk of airborne 
transmission, such as intensive care units.
Patients in the echocardiography laborato‑
ry should be categorized into 3 groups: 1) con‑
firmed COVID‑19, 2) suspected COVID‑19 (eg, 
awaiting for the results of PCR test or patients 
with respiratory tract infection), and 3) pa‑
tients with negative COVID‑19 PCR test or low 
probability of COVID‑19, based on the history 
and symptomatic status.23
Medical personnel in the echocardiography 
laboratory performing transthoracic exami‑
nations in patients with COVID‑19 (group 1) 
and suspected COVID‑19 (group 2) should be 
dressed in long sleeved surgical gown, gloves, 
be provided with eye protection with goggles 
or full face visor, and use FFP2, FFP3, or equiv‑
alent particulate respirators. In patients with 
low probability of COVID‑19 (group 3), based 
on the history and symptomatic status, we 
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Personnel should be appropriately trained and use 
maximum protection measures in the immediate vi‑
cinity of the patient, including at least FFP2, FFP3, 
or equivalent particulate respirator, long ‑sleeved 
surgical gowns, long surgical gloves, goggles, or full 
face visor, and sleeveless front waterproof apron.
Transesophageal echocardiography should 
not be performed in rooms where transthoracic 
examinations are carried out. If this is impos‑
sible, transesophageal examinations should be 
scheduled as the last examinations of the day.
It may be reasonable to relocate transesoph‑
ageal examinations to zones where protec‑
tive measures against airborne infections are 
Transesophageal echocardiography Trans‑
esophageal echocardiography is an  aerosol‑
‑generating procedure. Therefore, indications 
for that procedure should be significantly lim‑
ited primarily to suspected infectious endocar‑
ditis or acute mechanical valve dysfunctions, in 
cases in which it cannot be replaced with other 
imaging modalities. These limitations refer to 
all groups of patients: 1) confirmed COVID‑19, 2) 
suspected COVID‑19 (eg, awaiting for the results 
of PCR test or patients with respiratory tract 
infection), and 3) patients with negative COV‑
ID‑19 PCR test or low probability of COVID‑19, 
based on the history and symptomatic status.
FIGURE 1 Organization scheme for echocardiography laboratories at risk of COVID‑19 infection 
 Abbreviations: COVID‑19, coronavirus disease 2019; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography
Surgical masks for all staff  and patients
Echocardiography laboratory and COVID-19
Train your personnel in using personal protection 
equipment and applying procedures
Defer scheduled nonurgent examinations TEE should be considered a high‑risk procedure
Develop procedures to disinfect  the equipment and 
laboratory areas
Develop center‑specifi c indications and protocol  for 
TTE in COVID‑19 Limit indications to TEE
Rearrange the laboratory (eg, examination table 
arrangement, plasma air sterilizers) 
Develop a shortened protocol for TTE for indications 
other than COVID‑19
Consider relocating TEE in patients with COVID‑19 to areas 
ensuring better personnel protection
Evaluate appropriateness of TTE and TEE
Develop procedure for performing TTE outside echolab 
(in rooms of patients with COVID‑19)
Use full protection
 (risk of airborne transmission)
Consider using portable machines Aggregate TEE to limit donning and doffi  ng procedures
TTE TEE
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routinely used (eg, rooms dedicated for endo‑
scopic procedures). For the same reasons, we 
propose grouping transesophageal examina‑
tions to limit multiple donning and doffing 
procedures. Echocardiography machines (in‑
cluding probes) and beds should be disinfect‑
ed immediately after each examination. De‑
tailed instructions on how to clean transesoph‑
ageal probes should be developed in cooperation 
with the manufacturers.23,24
All personnel (including technicians and 
cleaning teams) should be trained in dressing 
and removing personal protective equipment 
(donning and doffing) according to the insti‑
tutional standard, which may be based on, for 
example, the recommendations of the Euro‑
pean Centre for Disease Prevention and Con‑
trol.27 Training should be performed repeated‑
ly in the presence of trained coaches. This ap‑
plies in particular to the staff directly exposed 
to aerosol ‑generating procedures. Useful train‑
ing videos are available online.28
The organization scheme for echocardiography 
laboratories at risk of COVID‑19 and protective 
equipment for transthoracic and transesophageal 




• Surgical mask (or FFP2, FFP3, or equivalent respirator in the areas of airborne transmission)
• Long sleeve gown
• Surgical gloves
• Eye protection (googles or visor shield)
• Closed working boots 
Surgical masks for all staff  and patients
Echocardiographic laboratory
COVID‑19 confi rmed or suspected 
Group patients as follows: 
1) Confi rmed COVID‑19
2) Suspected COVID‑19 
3) Negative COVID‑19 PCR or low probability of COVID‑19
TTE in groups 1 and 2
• FFP2, FFP3, or equivalent respirator
• Long sleeve gown
• Surgical gloves
• Eye protection (googles or visor shield)
TEE in groups 1,2, and 3
• FFP2, FFP3, or equivalent respirator
• Long sleeve gown
• Surgical gloves
• Eye protection (googles or visor shield)
• Waterproof sleeveless apron




FIGURE 2 Protective equipment for transthoracic and transesophageal echocardiography 
 Abbreviations: see FIGURE 1
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